Tag: US FDA
How to Trade the Gene Editing Excitement
By now, you’ve heard about gene editing.
Or, the ability to alter, remove, and even add a DNA sequence to help treat countless disorders we...
Eli Lilly Could Soon See US FDA Approval for Obesity Drug
Eli Lilly (LLY) could see higher highs.
All as new obesity drug trial results set it up for potential US FDA approval. In fact, in...
This Could be a Mega-Blockbuster for Eli Lilly
The obesity epidemic is still bursting at the seams.
At the moment, 1.9 billion people are overweight, with more than 650 million considered obese. In...
Altria Group Stock: Crisis May be Opportunity
Keep an eye on Altria Group (MO).
For one, the stock is brutally oversold on RSI, MACD, and Williams’ %R. It’s also oversold at double...
The Top Ways to Trade the Coming Psychedelics Boom
Psychedelics are going mainstream.
For one, the Director of the National Institutes of Health (NIH), Francis Collins recently touted the benefits of psilocybin and MDMA,...
This is Why Mind Med is Attractive Long-Term
Psychedelic stocks, like Mind Med (MNMD) could see higher highs.
All as such treatments show progress in the treatment of depression, anxiety, OCD, ADHD addiction, and...
Investors May Want to Use ACADIA Weakness as Opportunity
Don’t write off ACADIA Pharmaceuticals (ACAD) just yet.
In early March, the stock gapped from about $45.50 to $20.63. All after the US FDA rejected...
This is Why All Eyes are on Second Sight Medical Today
There’s a good deal of momentum with Second Sight Medical Products (EYES).
Over the last few days, all eyes were on EYES, as it exploded...
Johnson & Johnson (JNJ) May Be Ready to Rebound
Keep an eye on Johnson & Johnson (JNJ).
After pulling back from a high of $173.65, it caught support at $161.99. From here, the stock...
This is Why Moderna Could Run to $200, Near-Term
Vaccine news has created big opportunity.
Look at BioNTech for example. The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had...
Popular Post
